250 Binney Street
About Brammer Bio
Brammer Bio offers clinical and commercial services to supply vectors for in vivo gene therapy and ex vivo modified-cell based therapy. This includes process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patients' health. Brammer is owned by Ampersand Capital Partners, the only institutional investor in the company, and its founders.
CEO: Mark Bamforth
CSO: Richard O. Snyder
CFO: Steven H. Kasok
Please click here for Brammer Bio job opportunities.
18 articles with Brammer Bio
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
Under the agreement, Thermo Fisher will provide Amicus with immediate clinical and commercial manufacturing capabilities and capacity for Amicus’ intrathecal AAV Batten disease gene therapy programs.
Thermo Fisher Scientific Inc. announced that it has completed its previously announced acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, for approximately $1.7 billion in cash.
Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio
Balanced in-house and contract manufacturing strategy to provide clinical and commercial supply for Sangamo's growing pipeline of AAV-based genomic therapies
Significantly expands capabilities to support high-growth gene and cell therapy market
Brammer has about 600 staffers at its primary locations in Massachusetts and Florida. The company was projected to bring in $250 million in revenue this year.
Brammer is a sponsor and will participate in the MassBio Forum event in Boston, MA.
Brammer Bio ("Brammer"), a best-in-class viral vector contract development and manufacturing organization (CDMO) for companies developing gene-modified cell therapies and in vivo gene therapies, announces recent leadership appointments to support the growth of the organization.
Brammer Bio ("Brammer"), a best-in-class cell and gene therapy contract development and manufacturing organization (CDMO), was recognized by the Greater Gainesville Chamber of Commerce as the Manufacturing Company of the Year at its recent 2018 Business of the Year awards program.
Brammer Bio announces that a three-year, $200 million investment program is on track to establish over 30 suites for clinical and commercial viral vector supply for a broad pipeline of advanced gene therapies and gene-modified cell therapies.
Brammer Bio announces recent leadership appointments to support the growth of the organization.
The facility houses state-of-the-art equipment in cleanroom suites specially designed to accommodate a broad-range of gene therapy manufacturing process technologies.
Brammer Bio Expands Cell And Gene Therapy Capacity In Florida And Massachusetts, Partnering With Pall Life Sciences For Suspension And Adherent Platform Technologies
Brammer Bio Completes Expansion Of Cell And Gene Therapy Clinical Manufacturing Facilities In Florida
Brammer Bio Appoints Leading Commercial Manufacturing And Gene Therapy Expert As Chief Manufacturing Officer
Brammer Bio Announces Major Milestone In Establishing Commercial-Ready Gene Therapy Supply For The Industry